跳至主要内容
临床试验/jRCTs062230014
jRCTs062230014招募中不适用

Safety and efficacy of EUS-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: Pilot study

未提供0 个研究点目标入组 5 人开始时间: 2023年8月17日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
5
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
18age old over 至 No limit(—)
性别
All

入选标准

  • Age more than 18 years old
  • Patient who have been fully informed consent.
  • Pathologically confirmed PNEN with grade by EUS-FNA (WHO 2017 classification)
  • Tumor size 15 mm or less on CE-CT
  • non-functionnal PNEN or insulinom

排除标准

  • Allergy for contrast medium
  • Placement of a cardiac pacemaker
  • Within 2 mm of the distance between tumor and main pancreatic duct on radiographic images
  • Suspect of lymph node metastasis or distant metastasis on CE-CT.
  • Less than 50% of PT or less than 1.5 of INR
  • Less than 50,000 per microliter of PLT
  • Less than 30 mL/min/1.73m2 of eGFR
  • Administeration of more than 2 antithrombotic agents
  • Not less than 2 of performance status
  • Being pregnant or possibly pregnant
  • Less than 5 years of estimated prognosis
  • Patients judged as inappropriate candidate by the chief medical examiner

结局指标

主要结局

-

Safety

次要结局

未报告次要终点

研究者

发起方
未提供

相似试验